Now live: Pro — the full 13F research suite for serious investorsSee pricing →
BOONE CAPITAL MANAGEMENT LLC

Q1 2024 · 13F-HR

BOONE CAPITAL MANAGEMENT LLCholdings as filed

Filed 2024-05-15 · accession 0001214659-24-009294

$494.4M
Reported value
21
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
91529Y106UNMUNUM GROUP$55.0M11.1%1,025,027CommonSOLE
125523100CITHE CIGNA GROUP$47.9M9.69%131,926CommonSOLE
60855R100MOHMOLINA HEALTHCARE INC$35.2M7.12%85,716CommonSOLE
194014502ENOVENOVIS CORPORATION$35.1M7.11%562,739CommonSOLE
071813109BAXBAXTER INTL INC$29.8M6.03%697,957CommonSOLE
379577208GMEDGLOBUS MED INC$28.4M5.75%529,825CommonSOLE
08579W103BERYEURBERRY GLOBAL GROUP INC$27.2M5.51%450,101CommonSOLE
03209R103AMPHAMPHASTAR PHARMACEUTICALS IN$26.6M5.39%606,688CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$25.5M5.15%310,462CommonSOLE
090572207BIOBIO RAD LABS INC$25.0M5.06%72,344CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$23.3M4.72%531,967CommonSOLE
87650L103TARSTARSUS PHARMACEUTICALS INC$22.1M4.48%609,104CommonSOLE
235851102DHRDANAHER CORPORATION$16.4M3.32%65,811CommonSOLE
59064R109MLABMESA LABS INC$14.6M2.96%133,394CommonSOLE
68752M108OFIXORTHOFIX MED INC$14.1M2.86%974,502CommonSOLE
92556V106VTRSVIATRIS INC$13.5M2.74%1,133,591CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$12.5M2.54%291,403CommonSOLE
421906108HCSGHEALTHCARE SVCS GROUP INC$11.6M2.34%926,455CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$11.4M2.30%451,898CommonSOLE
70805E109PNTGPENNANT GROUP INC$11.1M2.24%564,192CommonSOLE
74766Q101QTRXQUANTERIX CORP$7.8M1.57%330,151CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.